IACS-8803

IACS-8803 is a **preclinical small-molecule cyclic dinucleotide STING agonist** being developed by **MD Anderson Cancer Center** for **cancer immunotherapy**. It is described as a 2',3'-linked phosphorothioate diadenosine monophosphate analog with a 2'-fluorine modification and has been reported to potently activate the **STING signaling pathway**, driving interferon beta production and downstream priming of antitumor cytotoxic T-cell responses. In preclinical murine melanoma and pancreatic cancer models, IACS-8803 showed robust systemic antitumor activity and superior responses versus benchmark STING agonist comparators, supporting its development for neoplasms.